How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
CorMedix is back in focus as analysts reset their price targets, with some moving to $16 from $20, others to $13 from $15, and a few cutting as low as $9. These changes follow updated DefenCath revenue guidance and management commentary, which have prompted both cautious reductions and continued upside cases relative to current levels. As you read on, you will see how to track these shifting targets and use the evolving CorMedix story to frame your own view. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value CorMedix. What Wall Street Has Been Saying ?? Bullish Takeaways Truist cut its CorMedix target to $16 from $20 but kept a Buy rating, signaling that it still sees upside potential relative to current trading levels, even after factoring in the new DefenCath revenue outlook. Leerink reduced its target to $13 from $15 and maintained an Outperform rating on the shares, which indicates the firm continues to v
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink [Yahoo! Finance]Yahoo! Finance
- CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference [Yahoo! Finance]Yahoo! Finance
- CorMedix (CRMD) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations [Yahoo! Finance]Yahoo! Finance
- CorMedix (CRMD) had its price target lowered by Needham & Company LLC from $15.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
CRMD
Earnings
- 3/5/26 - Miss
CRMD
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/6/26 - Form 8-K
- 3/5/26 - Form 10-K
- CRMD's page on the SEC website